zanamivir placebo + moxifloxacin placebo

zanamivir placebo + moxifloxacin placebo is a double-placebo control arm used in a Phase I clinical trial conducted by GSK. The study was a randomized, four-way crossover trial designed to evaluate the effect of intravenous (IV) zanamivir on cardiac conduction (specifically the QT interval) in healthy volunteers. In this specific treatment arm, participants received a single dose of an intravenous placebo (matching the IV zanamivir formulation) and a single dose of an oral placebo (matching the moxifloxacin positive control). This arm serves as the negative control to establish a baseline for cardiac conduction measurements and to validate the sensitivity of the study using moxifloxacin as a positive control. Zanamivir is a neuraminidase inhibitor developed for influenza, while moxifloxacin is a fluoroquinolone antibiotic commonly used as a positive control in Thorough QT (TQT) studies.

Other names

zanamivir placebomoxifloxacin placebo